What Is Mounjaro® (Tirzepatide)? Eli Lilly's New GIP/GLP-1 Medication Explained

The Core Mechanism: Why Two Receptors Matter

Tirzepatide is the first approved medication to act as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Earlier drugs in this class, such as semaglutide (Ozempic, Wegovy), target only the GLP-1 receptor. Adding GIP receptor activation appears to produce additive effects on insulin secretion, appetite suppression, and fat metabolism that neither pathway achieves alone.

How GLP-1 Receptor Activation Works

GLP-1 is released from intestinal L-cells after eating. When a drug activates the GLP-1 receptor, it stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and signals the hypothalamus to reduce appetite. These combined actions lower post-meal blood glucose and reduce total caloric intake over time.

What GIP Adds to the Equation

GIP is secreted by intestinal K-cells and was historically considered a weaker partner to GLP-1 in diabetes treatment. Preclinical and early clinical data suggest that simultaneously activating the GIP receptor potentiates the appetite-suppressing and insulin-sensitizing effects of GLP-1 agonism. A 2023 paper in Cell Metabolism proposed that GIP receptor activation in adipose tissue may also directly reduce fat accumulation, though the exact mechanism in humans is still under study [1].

The Structural Difference From Semaglutide

Tirzepatide is a synthetic 39-amino-acid peptide based on the native GIP sequence, modified to also bind GLP-1 receptors with high affinity. Semaglutide is a 94% homologous analogue of native GLP-1. The structural distinction is not cosmetic: it explains why tirzepatide produces a qualitatively different receptor-activation profile, which translates into the larger weight-loss and glycemic outcomes seen in head-to-head trials [2].

FDA Approval History and Indications

Mounjaro for Type 2 Diabetes (May 2022)

The FDA granted approval for Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes on May 13, 2022. The approval was supported by the SURPASS clinical trial program, a six-trial series enrolling more than 5,000 participants across multiple countries [3].

The label specifies tirzepatide should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are the same contraindications carried by GLP-1 receptor agonists as a class.

Zepbound for Chronic Weight Management (November 2023)

On November 8, 2023, the FDA approved tirzepatide under the brand name Zepbound® specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [4].

This approval made tirzepatide the second injectable weight-loss medication approved since semaglutide 2.4 mg (Wegovy) received its obesity indication in June 2021.

Clinical Trial Evidence: SURPASS and SURMOUNT

SURPASS-2: Tirzepatide vs. Semaglutide in Type 2 Diabetes

SURPASS-2 (N=1,879) directly compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg once weekly over 40 weeks in adults with type 2 diabetes inadequately controlled on metformin. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg (P<0.001). Body weight fell by 11.2 kg with tirzepatide 15 mg compared with 5.7 kg with semaglutide 1 mg [2].

The American Diabetes Association's 2023 Standards of Care note that tirzepatide demonstrated "superior glycemic and weight reduction compared with semaglutide 1 mg" in this trial [5].

SURMOUNT-1: Tirzepatide for Obesity Without Diabetes

SURMOUNT-1 (N=2,539) enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity but without diabetes. Participants received tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, once weekly for 72 weeks alongside lifestyle counseling. Results published in the New England Journal of Medicine in 2022 showed the following [6]:

• Tirzepatide 5 mg: mean weight loss of 15.0% of body weight
• Tirzepatide 10 mg: mean weight loss of 19.5% of body weight
• Tirzepatide 15 mg: mean weight loss of 20.9% of body weight (22.5% among participants who completed treatment)
• Placebo: mean weight loss of 3.1% of body weight

Approximately 37% of participants on tirzepatide 15 mg lost 25% or more of their body weight, a threshold never reached by any previously approved anti-obesity drug.

SURMOUNT-2: Tirzepatide in Obesity With Type 2 Diabetes

SURMOUNT-2 (N=938) tested tirzepatide in participants who had both obesity and type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight loss of 15.7% versus 3.3% for placebo (P<0.001), and 82% of tirzepatide-treated participants achieved HbA1c below 7.0% compared with 32% in the placebo group [7].

SURMOUNT-MMO: Cardiovascular Outcomes

The SURMOUNT-MMO trial is evaluating tirzepatide's effect on major adverse cardiovascular events in adults with obesity. Full results are pending, but interim enrollment and safety data reported to the FDA support the continued favorable benefit-risk profile seen in the weight-loss program. Cardiovascular outcome data for tirzepatide in the obesity setting are expected in late 2025 or 2026.

Dosing Schedule and Titration

Tirzepatide is initiated at 2.5 mg once weekly for four weeks. The dose is then increased in 2.5 mg increments every four weeks as tolerated, up to a maximum of 15 mg weekly. The slow titration schedule exists specifically to reduce gastrointestinal side effects, particularly nausea and vomiting, during the early weeks of treatment.

Dose Steps at a Glance

| Week Range | Dose | |---|---| | Weeks 1 to 4 | 2.5 mg once weekly | | Weeks 5 to 8 | 5 mg once weekly | | Weeks 9 to 12 | 7.5 mg once weekly | | Weeks 13 to 16 | 10 mg once weekly | | Weeks 17 to 20 | 12.5 mg once weekly | | Week 21 onward | 15 mg once weekly (maximum) |

Individual patients may remain at a lower maintenance dose if the maximum is not tolerated. Clinical response at 5 mg or 10 mg can still be meaningful; the SURMOUNT-1 arm on 5 mg achieved 15.0% weight loss at 72 weeks.

How to Inject Tirzepatide

Tirzepatide comes in single-dose auto-injector pens. The injection is administered subcutaneously in the abdomen, thigh, or upper arm. Patients rotate injection sites each week. The medication does not need to be shaken. Pens are stored in the refrigerator (36°F to 46°F, or 2°C to 8°C) and may be kept at room temperature up to 77°F (25°C) for up to 21 days.

Side Effects and Safety Profile

Common Gastrointestinal Side Effects

The most frequently reported adverse events in SURPASS and SURMOUNT trials were gastrointestinal in nature. In SURMOUNT-1, nausea occurred in 31% of participants on 15 mg versus 9% on placebo, diarrhea in 23% versus 11%, and vomiting in 16% versus 5% [6]. These effects were most common during dose escalation and generally decreased after the maintenance dose was stable for several weeks.

Eating smaller meals, avoiding high-fat or spicy foods, and staying well hydrated reduced symptom severity in the majority of patients who reported early intolerance.

Serious but Rare Risks

The FDA-approved labeling includes a boxed warning regarding the potential risk of thyroid C-cell tumors, based on rodent studies. No cases of medullary thyroid carcinoma have been causally attributed to tirzepatide in human trials to date, but the label requires providers to counsel patients on this theoretical risk and to screen for relevant personal or family history before prescribing.

Other serious but uncommon risks include:

• Acute pancreatitis (patients should stop tirzepatide and seek evaluation if severe abdominal pain occurs)
• Acute gallbladder disease, including cholelithiasis and cholecystitis
• Hypoglycemia, particularly when tirzepatide is combined with insulin or sulfonylureas
• Acute kidney injury, secondary to dehydration from vomiting or diarrhea
• Hypersensitivity reactions, including anaphylaxis and angioedema (rare)

Heart Rate Increase

Tirzepatide increases resting heart rate by approximately 2 to 4 beats per minute on average, similar to other GLP-1 receptor agonists. Patients with pre-existing arrhythmias or those taking medications that affect heart rate should be monitored accordingly.

Who Qualifies for Tirzepatide?

FDA-Approved Indications

Mounjaro (tirzepatide for diabetes): Adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not approved for type 1 diabetes and has not been studied adequately in that population.

Zepbound (tirzepatide for obesity): Adults with an initial BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity, combined with a reduced-calorie diet and increased physical activity.

Who Should Not Take Tirzepatide

Tirzepatide is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Known serious hypersensitivity to tirzepatide or any component of the formulation
• Pregnancy (weight-loss therapy should be discontinued two months before a planned pregnancy)

The FDA label also advises caution in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy if tirzepatide is added to insulin therapy.

Tirzepatide vs. Semaglutide: A Direct Comparison

The question most patients ask is whether tirzepatide produces better results than semaglutide. Based on available trial data, the answer is yes for both weight loss and glycemic control, though the comparison has important caveats.

The table below summarizes the key head-to-head and parallel data points:

| Metric | Tirzepatide 15 mg | Semaglutide 2.4 mg (Wegovy) | |---|---|---| | Trial | SURMOUNT-1 (72 wk) | STEP-1 (68 wk) | | Population | Obesity without diabetes | Obesity without diabetes | | Mean weight loss | 20.9% of body weight | 14.9% of body weight | | Placebo weight loss | 3.1% | 2.4% | | ≥20% weight loss achieved | 57% of participants | 32% of participants | | HbA1c reduction (T2D, vs. Sema 1 mg) | 2.46 pp (SURPASS-2) | 1.86 pp (SURPASS-2) |

SURMOUNT-1 and STEP-1 are not identical trials, so the populations and study conditions are not perfectly matched. A prospective head-to-head weight trial comparing tirzepatide against semaglutide 2.4 mg specifically in the obesity indication has not yet been published. The SURPASS-2 comparison remains the most direct evidence, and it used semaglutide 1 mg (diabetes dose), not the 2.4 mg obesity dose.

With that context, the magnitude of difference in SURMOUNT-1 versus STEP-1 is large enough that most clinicians treating obesity consider tirzepatide the stronger agent for weight reduction at this time.

Cost, Insurance, and Access

List Price and Coverage Challenges

The list price of Mounjaro and Zepbound in the United States was approximately $1,023 and $1,060 per month respectively as of early 2025, before insurance discounts or manufacturer savings programs. Coverage varies dramatically by plan. Many commercial plans that cover Ozempic or Victoza for diabetes also cover Mounjaro for type 2 diabetes. Zepbound's obesity indication faces more coverage barriers because many employer and Medicare Part D plans historically excluded weight-loss drugs.

The Treat and Reduce Obesity Act, if passed, would require Medicare to cover FDA-approved obesity medications. As of mid-2025, it has not been signed into law.

Eli Lilly Savings Programs

Eli Lilly offers a savings card for commercially insured patients that may reduce out-of-pocket cost to as low as $25 per month for Mounjaro and a similar program for Zepbound. Eligibility requirements apply, and these programs do not extend to patients with federal insurance (Medicare, Medicaid). Patients should verify current eligibility at Eli Lilly's official program pages or through their pharmacy.

Compounded Tirzepatide

During FDA-declared drug shortages, compounding pharmacies produced tirzepatide preparations. The FDA declared the shortage of tirzepatide resolved in October 2024, at which point 503B outsourcing facilities were given a wind-down period and 503A compounding pharmacies were required to stop producing copies for individual patients. Patients receiving compounded tirzepatide should discuss transition to the branded product with their prescriber.

What to Expect in the First 12 Weeks

Patients starting tirzepatide should set realistic expectations for the early weeks. The first four weeks at 2.5 mg are primarily a tolerability period. Significant weight loss rarely occurs in this phase. Most patients report the most noticeable appetite reduction after the dose reaches 7.5 mg or 10 mg, typically around weeks nine to twelve.

Blood glucose improvement in people with type 2 diabetes often appears within the first two to four weeks because the incretin effect on post-meal insulin secretion is active even at the lowest dose. Weight change at that stage is modest.

Gastrointestinal symptoms peak around dose escalation windows. Having a clear plan for managing nausea, including meal timing and portion control, reduces the risk of discontinuation in the early weeks when side effects are most prominent.

Providers at HealthRX typically schedule a check-in at four weeks and again at twelve weeks to assess tolerance, review any laboratory changes, and confirm the dose escalation is on track.